Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 18 of 18

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract May 2006

Loss of Quality of Life Due to Visual Disease: A Preference Based (Utility) Assessment

S.M. Kymes; R.F. Nease, Jr.; W. Sumner; M.O. Gordon

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):1550.

ARVO Annual Meeting Abstract May 2006

Age in Keratoconus

K. Zadnik; B.S. Wilson; M.O. Gordon; CLEK Study Group

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):2951.

ARVO Annual Meeting Abstract May 2006

Visual Field Quality Control in the Ocular Hypertension Treatment Study (OHTS) and the Optic Neuritis Treatment Trial (ONTT)

J.L. Keltner; C.A. Johnson; K.E. Cello; J. Fan; R.A. Levine; S.E. Bandermann; M.A. Kass; M.O. Gordon; R.W. Beck; Ocular Hypertension Treatment Study Group

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):3394.

ARVO Annual Meeting Abstract May 2006

Time Dependent Changes in Central Corneal Thickness in the Ocular Hypertension Treatment Study (OHTS)

J.D. Brandt; J.A. Beiser; M.O. Gordon; S.C. Lin; M.Y. Alexander; M.A. Kass; OHTS Study Group

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):4422.

ARVO Annual Meeting Abstract May 2005

Comparison of IOP Response to Topical Beta–Adrenergic Antagonists and Prostaglandin Analogues in African Americans and Whites: The Ocular Hypertension Treatment Study (OHTS)

S.L. Mansberger; B.A. Hughes; M.O. Gordon; S.L. Spaner; J.A. Beiser; G.A. Cioffi; M.A. Kass; Ocular Hypertension Treatment Study (OHTS) Group

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):2449.

ARVO Annual Meeting Abstract May 2005

Test–Retest Reproducibility of Determining Optic Disc Deterioration in the Ocular Hypertension Treatment Study (OHTS):

R. Parrish; J.C. Schiffman; W.J. Feuer; D.R. Anderson; D.L. Budenz; M.C. Wells–Albornoz; M.A. Kass; M.O. Gordon; Ocular Hypertension Treatment Study Group

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):3630.

ARVO Annual Meeting Abstract May 2005

Baseline Topographic Optic Disc Measurements Are Associated With the Development of Primary Open Angle Glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the OHTS

L.M. Zangwill; R.N. Weinreb; J.A. Beiser; G.A. Cioffi; A.L. Coleman; G. Trick; J.M. Liebmann; M.A. Kass; M.O. Gordon; OHTS CSLO Ancillary Study Group

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):3631.

ARVO Annual Meeting Abstract May 2005

Visual Field Quality Control in the Ocular Hypertension Treatment Study (OHTS): and in the 10–Year Optic Neuritis Treatment Trial (ONTT) Follow–Up Study

J.L. Keltner; C.A. Johnson; K.E. Cello; J. Fan; S.E. Bandermann; M.A. Kass; M.O. Gordon; R.W. Beck; Ocular Hypertension Treatment Study Group

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):3738.

ARVO Annual Meeting Abstract May 2005

A Longitudinal Study of the Quality of Life of People With Keratoconus: A Report From the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study

S.M. Kymes; J.J. Walline; K. Zadnik; B.S. Wilson; M.O. Gordon; CLEK Study Group

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):4945.

ARVO Annual Meeting Abstract May 2005

Predictors of Visual Acuity Loss in Keratoconus

K. Zadnik; K.B. Schechtman; L.J. Davis; R.E. Gundel; D.P. Libassi; C.E. Riley; C.E. Rosenstiel; B.S. Wilson; M.O. Gordon; CLEK Study Group

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):4947.

ARVO Annual Meeting Abstract May 2004

Detection and predictive value of optic disc hemorrhages in the Ocular Hypertensive Treatment Study

D.L. Budenz; J.A. Beiser; J.R. Piltz; R.K. Parrish; D.R. Anderson; M.O. Gordon; M.A. Kass; Ocular Hypertension Treatment Study Group

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):940.

ARVO Annual Meeting Abstract May 2004

A Predictive Model for the Development of POAG in the Ocular Hypertension Treatment Study Excluding Pattern Standard Deviation (PSD) and Vertical Cup/Disc Ratio (VC/D)

A.L. Coleman; M.O. Gordon; J.A. Beiser; M.A. Kass; Ocular Hypertension Treatment Study

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):955.

ARVO Annual Meeting Abstract May 2004

Quality of Life and Penetrating Keratoplasty in Patients with Keratoconus – Results From the Collaborative Longitudinal Evaluation of Keratoconus (CLEK)

S.M. Kymes; B.S. Wilson; M.O. Gordon; CLEK Study Group

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):1376.

ARVO Annual Meeting Abstract May 2004

Types of Visual Field Abnormalities that Subsequently Become Visual Field Primary Open–Angle Glaucoma in the Ocular Hypertension Treatment Study (OHTS)

J.L. Keltner; C.A. Johnson; J. Fan; K.E. Cello; M.A. Kass; M.O. Gordon; Ocular Hypertension Treatment Study Group

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):2134.

ARVO Annual Meeting Abstract May 2003

Is There a Penalty for Delayed Treatment in Ocular Hypertensives? Evidence from the Ocular Hypertension Treatment Study (OHTS)

D.K. Heuer; E.J. Higginbotham; M.A. Kass; R.K. Parrish, II; M.O. Gordon; Ocular Hypertenstion Study Group

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):104.

ARVO Annual Meeting Abstract May 2003

Classification of Glaucomatous Visual Field Abnormalities In the Ocular Hypertension Treatment Study (OHTS)

J.L. Keltner; C.A. Johnson; J. Fan; K.E. Cello; M.O. Gordon; M.A. Kass; Ocular Hypertension Treatment Study Group

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):75.

ARVO Annual Meeting Abstract May 2003

Visual Acuity Loss in Keratoconus

K. Zadnik; K.B. Schechtman; B.A. Wilson; J.T. Barr; T.B. Edrington; T.T. McMahon; D.F. Everett; M.O. Gordon; CLEK Study Group

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):1308.

ARVO Annual Meeting Abstract May 2003

Topical Treatment of Persons with Ocular Hypertension: Who Should be Treated? An Economic Evaluation from the Ocular Hypertension Treatment Study (OHTS)

S.M. Kymes; M.A. Kass; M.O. Gordon

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):3168.

Advertisement